Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2026)

Crinetics Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $114.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 20.91% year-over-year to $114.3 million; the TTM figure through Mar 2026 stood at $114.3 million (up 20.91% YoY), while the FY2025 annual figure was $101.5 million, down 61.62% from the prior year.
• Cash & Equivalents was $114.3 million for Q1 2026 at Crinetics Pharmaceuticals, up from $101.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.2 billion in Q2 2025 to a low of $30.9 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $203.1 million across 5 years, with a median of $110.9 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 83.11% in 2022, then soared 861.14% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $34.0 million in 2022, then surged by 61.59% to $54.9 million in 2023, then soared by 381.89% to $264.5 million in 2024, then sank by 61.62% to $101.5 million in 2025, then grew by 12.61% to $114.3 million in 2026.
• The last three Cash & Equivalents figures came in at $114.3 million (Q1 2026), $101.5 million (Q4 2025), and $110.9 million (Q3 2025), per Business Quant data.